Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

University of Ulsan25 enrolled

Overview

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Bleeding Tachycardia Dyspnea

Interventions

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult uremic patients with one or more antiplatelet medication, * prolonged collagen/epinephrine (CEPI) closure time, * need for emergent hemodialysis and * subsequent catheter insertion Exclusion Criteria: * acute coronary syndrome, * hemophilia, and nephrogenic diabetes insipidus, * allergy against desmopressin

Outcomes

Primary Outcomes

collagen-epinephrine closure time

In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.

Time frame: 1 hour

Secondary Outcomes

Bleeding after procedure

we observe incidence of bleeding complication after procedure

Time frame: 1-4 hr after procedure